No ratings

Good Thursday afternoon, folks, or good Friday morning (or maybe even Friday afternoon, for some of you). Whenever you get around to reading the newsletter, we hope things are going well for you. Anyway, we've got a handful of things to get through this afternoon, so let's not tarry.

First, back on June 2nd when we first introduced Moleculin Biotech (MBRX) to you, we promised we'd keep an eye out for any relevant news, and we'd also keep an eye out for any trading opportunities with the stock. We just ran across one we liked.

The nearby chart of MBRX speaks for itself. Like pretty much every other IPO out there, Moleculin Biotech shares had to get pushed around, and pay its dues. While it may not be done paying all of its dues yet, the first wave of hazing seems to have come to a close, setting up a rebound rally effort. The downtrend reversed course in a relatively decided fashion on Wednesday, and the bulls followed through on Thursday.

No ratings

Happy hump-day, friends and fellow traders.

Well, I don't know what the market was expecting in the way of interest rate increases from the Federal Reserve today, but what they got was less then thrilling to them. Stocks were inching higher headed into the 2:00 pm EST announcement, but they started to give up ground when Janet Yellen decided no change was necessary at this time. Inflation remains plenty tame, and there are some soft spots for the economy.

It's also pretty clear the Federal Reserve's voting members are collectively on the fence for the long run. Again though, that's nothing new. The only thing that really changed was a slight reel-in of future rate-hike plans.

No ratings

Hey everybody, want to make a quick buck?

Of course everybody wants to make a quick buck. Problem is, it's easier said than done, and in the rare case where it is possible to do so, it's pretty unusual to be able to do so consistently.

I tell you what though.... after being a subscriber to the Under the Radar Movers service for just a little over three weeks, James Brumley and his team have indeed made it possible to not only make a quick buck, but they've made it possible to do so consistently.

No ratings

Welcome back to the trading week, friends and fellow traders, though I certainly wish we could have started the new week on a more bullish foot. Then again, we've talked about this a few times of late... we knew something like this could be in the cards. At least the market hasn't yet stumbled below the point of no return.

In any case, we've got a couple of updates for the site's Featured Stocks.

You may have seen it, but if not, Staffing 360 Solutions (STAF) opened another Monroe Staffing branch in North Carolina. That's the company's third in the state, the 20th overall.

No ratings

Howdy ladies and gents.

Did everybody see what happened to AbbVie (ABBV) yesterday? Not that a 3% setback is earth-shattering, but it's nothing to sneeze at either.

It wasn't the pullback from ABBV that's so interesting though - it was the reason for the setback. In simplest terms, recurrent/refractory small-cell lung cancer (SCLC) drug Rova-T didn't perform well enough to suit investors in its early-stage trials. It performed, but given that AbbVie spent $5.8 billion to acquire the drug's developer, Stemcentrx, one would have expected fireworks.